Report copyright - Repurposed Compounds NP-135 and NP-160 Reduce Fibrosis in … · 2019. 12. 16. · • Cenicriviroc (40 mg/kg) – a dual-CCR2/CCR5 antagonist in clinical trials for NASH2 – reduced
Please pass captcha verification before submit form
Please pass captcha verification before submit form